PRESTRELSKI STEVEN (Chief Scientific Officer) sold 2.3% of their position (10K shares) of XERIS PHARMACEUTICALS INC on the open market
Open‑market sale worth $57.2K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/12/2021ACC: 0001346302-21-000002
Officer· Chief Scientific Officer
Since Dec 2018
-10K
Net shares
Net seller
$57.2K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
10K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−10K
Price / share
$5.72
Trade value
$57.24K
% of position
2.3%
1/11/2021
426.82K→416.82K
Total
Net shares
−10K
Net value
-$57.24K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/11/2021 | S · Sale | −10K | $5.72 | $57.24K | 2.3% | 426.82K | 416.82K |
| Total | −10K | -$57.24K | ||||||
Derivative Transactions0
No derivative transactions reported